Cidara Therapeutics, Inc.
CDTX
$19.44
$0.261.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -94.52% | -86.96% | -78.78% | -71.62% | -63.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -94.52% | -86.96% | -78.78% | -71.62% | -63.87% |
| Cost of Revenue | 95.52% | -34.88% | -48.68% | -50.75% | -52.51% |
| Gross Profit | -423.77% | -46.46% | -951.30% | -340.59% | -4.04% |
| SG&A Expenses | 51.80% | 7.25% | -16.65% | -28.81% | -33.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 83.73% | -24.95% | -41.29% | -45.90% | -48.60% |
| Operating Income | -237.10% | -29.16% | -104.82% | -27.13% | 19.23% |
| Income Before Tax | -579.40% | -273.27% | -665.43% | -20.00% | 24.76% |
| Income Tax Expenses | -- | -97.50% | -108.01% | -94.49% | -94.49% |
| Earnings from Continuing Operations | -578.99% | -270.23% | -649.61% | -18.60% | 25.32% |
| Earnings from Discontinued Operations | -78.41% | 290.49% | -78.26% | -200.00% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -640.60% | -227.37% | -789.84% | -195.12% | 31.72% |
| EBIT | -237.10% | -29.16% | -104.82% | -27.13% | 19.23% |
| EBITDA | -237.93% | -29.14% | -105.60% | -27.39% | 19.22% |
| EPS Basic | -503.51% | -180.89% | -585.85% | -127.84% | 48.36% |
| Normalized Basic EPS | -100.98% | 7.35% | -83.37% | 2.69% | 39.79% |
| EPS Diluted | -502.81% | -180.85% | -584.48% | -80.97% | 52.92% |
| Normalized Diluted EPS | -100.98% | 7.35% | -46.77% | 15.23% | 44.87% |
| Average Basic Shares Outstanding | 45.07% | 21.79% | 16.69% | 24.72% | 25.13% |
| Average Diluted Shares Outstanding | 45.07% | 21.79% | 10.18% | 17.29% | 17.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |